IPIX >> 10.8.18
Previous Close
10/05/2018 0.24
52-Week High
12/06/2017 1.17
52-Week Low
10/01/2018 0.18
Price Performance (Last 52 Weeks)
10/05/2018 -66.19%
Volume 205,005
Volume (10 day Average) 483,260
Volume (90 day Average) 264,907
*imo*
when NR is significantly upside down
NR has to make good news looks bad (and on volume when able)
and bad news look fatal
NR just filled my bid @ 20c (6950 shares) @ 11:09:49 .. that they wouldn't *fill* yesterday @ 22c .. and they also didn't show it yesterday either ..
11:09:49 0.20 6950 OTO
90 day volume algo hit in approx first 15 mins of today's *trading*
10 day volume algo hit just b4 10:30AM (one hour trading)
clearly a *volume* day .. curious to see how marked ..
reminder *legal* due out AH's today
my next bid @ 155 .. then 105 .. NR needs *volume* and needs actual *sells*
currently ..
Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.1975Down -0.0405 (-17.02 %)AS OF 11:21:53AM ET 10/09/2018
Last Trade 0.1975
Trade Time 11:21:53am ET
Change -0.0405
% Change -17.02%
Bid 0.195
Bid Size 10000
Ask 0.20
Ask Size 44400
Open 0.238
Day High 0.27
Day Low 0.1975
Previous Close
10/08/2018 0.238
52-Week High
12/06/2017 1.17
52-Week Low
10/01/2018 0.18
Price Performance (Last 52 Weeks) ** imo leeway
10/08/2018 -66.05%
Volume 649,125
Volume (10 day Average) 480,140
Volume (90 day Average) 265,908
4kids
Quote:
This deal with a private family guarantees that what happened to OCAT will NOT happen to IPIX. I am very happy to hear news of this deal.
OCAT was attacked by Mako, first with articles on Seeking Alpha (the article even did the same thing about "empty offices" ) and then Adam Feuerstein started attacking them on Twitter. 3 or 4 days before OCAT was due to release data on their pivotal clinical trial, Feuerstein tweeted that he had "advance information" that the trial had failed badly. Their stock tanked even further.
Then OCAT released their data -- it was stellar -- truly great results for their clinical trial.
BUT -- the stock price did not recover even to the levels it was before the Feuerstein attack. And, OCAT had had a series of bad CEOs who got the company into high-interest-rate debt, which they could not service.
So, a couple of weeks after the great clinical trial data, OCAT sold itself to avoid bankruptcy. Almost all shareholders lost a lot of money, as the company was sold at a fire-sale valuation that was less than what its pre-clinical-trial price was that many long-term investors had as their basis.
With this deal, Leo is sending a message to Big Pharma that they either have to offer a fair price (regarding the term sheet, AND to other potential partners) because IPIX is NOT going to be forced into a horrible deal, as OCAT was.
Take that, Mako and Feuerstein.
(3)
(0)
